Treatment of lymphoid cell malignancy with In-114m labelled autologous lymphocytes

H. L. Sharma, R. A. Cowan, B. Murby, S. Owens, P. M. Nuttall, D. Gunton, A. M. Smith, J. Chang, D. Crowther

    Research output: Chapter in Book/Report/Conference proceedingConference contribution

    Abstract

    This paper is a preliminary report of a clinical trial for the treatment of patients with refractory chronic lymphocytic leukaemia, using autologous In-114m - labelled lymphocytes. Fourteen patients have been treated so far with doses ranging from 69 to 211 MBq. All patients had progressive low grade NHL, resistant to chemotherapy and conventional radiotherapy. Following the intravenous administration of radiolabelled autologous lymphocytes 53% (range 33-92%) of the activity accumulated in the spleen, 35% (21-64%) in the liver and 5% in the bone marrow. The initial response in all patients was a rapid decrease in lymphocyte count in peripheral blood. 10 of the 14 (72%) patients showed a response to the treatment. In 2 patients, there was a complete response which lasted 24 and 36 months respectively. 8 patients showed a partial response of 2 to 17 months duration. None of the patients experienced any subjective toxicity although myelosuppression was seen in all patients. This is a novel concept for the administration of therapeutic radiation in a selective way for the treatment of lymphoid cell malignancy and has produced significant antitumour effect in patients with highly resistant disease. The trial is ongoing and a full report will be published on its completion.
    Original languageEnglish
    Title of host publicationAnticancer Research|ANTICANCER RES.
    Place of PublicationRome, Italy
    Pages1815-1821
    Number of pages6
    Volume17
    Publication statusPublished - 1997

    Keywords

    • In-114m-labelled lymphocytes
    • Lymphoid malignancy
    • Spleen targeting

    Fingerprint

    Dive into the research topics of 'Treatment of lymphoid cell malignancy with In-114m labelled autologous lymphocytes'. Together they form a unique fingerprint.

    Cite this